

Attorney Docket No.: 21327-701-01

## SEOUENCE LISTING

```
<110> Gill, Parkesh
     Masood, Rizwan
<120> METHOD AND COMPOSITION FOR TREATMENT OF
  KAPOSI'S SARCOMA
<130> 21327-701-01
<140> US 09/487,023
<141> 2000-01-19
<150> US 60/037,004
<151> 1997-01-31
<150> US 09/016,541
<151> 1998-01-30
<160> 33
<170> FastSEQ for Windows Version 4.0
<210> 1
<211> 21
<212> DNA
<213> Artificial Sequence
<223> Antisense oligonucleotide to a naturally occuring
      sequence
<400> 1
                                                                          21
agacagcaga aagttcatgg t
<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
<223> Antisense oligonucleotide to a naturally occurring
      sequence
<400> 2
                                                                          21
tggcttgaag atgtactcga t
<210> 3
<211> 21
<212> DNA
<213> Artificial Sequence
<220>
```

<223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> attgca	3 agcag ccccacatc g	21
<210><211><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> gcagco	4 cccca catcggatca g	21
<210><211><212><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> cccaca	5 atcgg atcaggggca c	21
<210><211><212><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> tcggal	6 tcagg ggcacacagg a	21
<210><211><212><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> cagggg	7 gcaca caggatggct t	21

<210><211><212><212><213>	21	·	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		
<400> cacaca	8 aggat ggcttgaaga t		21
<210><211><212><212><213>	21		
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		
<400> acacaç	9 ggatg gcttgaagat g		21
<210><211><212><213>	21		
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		
<400>	10 gatgg cttgaagatg t		21
<210><211><212><212><213>	21		
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		
<400> acagg	11 atggc ttgaagatgt a		21
<210><211><212><212><213>	21		
<220>			

<223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> caggat	12 Egget tggagatgta c	21
<210><211><212><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> aggato	13 ggett ggagatgtae t	21
<210><211><212><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	•
<400> ggatg	14 gcttg aagatgtact c	21
<210><211><212><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> gatgg	15 cttga agatgtactc g	21
<210><211><212><212><213>	21	
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> atggc	16 ttgaa gatgtactcg a	21

<210><211><211><212><213>	21			•
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma			
<400> ggcttg	17 gaaga tgtactcgat c			21
<210><211><211><212><213>	21			
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma			
<400> gcttga	18 aagat gtactcgatc t			21
<210><211><212><212><213>	21			
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma			
<400> cttgaa	19 agatg tactcgatct c			21
<210><211><212><212><213>	20			
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma			
<400> ggatg	20 gcttg aagatgtact			20
<210><211><212><212><213>	19			
<220>	*	RECT	A. 40	

<223> VI	EGF antisense oligonucleotide in Kaposi's arcoma, ovarian carcinoma, and melanoma	
<400> 2 ggatggc		19
<210> 2: <211> 1: <212> D: <213> A:	8	
<220> <223> V	EGF antisense oligonucleotide in Kaposi's arcoma, ovarian carcinoma, and melanoma	
<400> 2 ggatggc	2 ttg aagatgta	18
<210 > 2 <211 > 2 <212 > D <213 > A		
<220> <223> V s	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> 2 ggcttga	23 aaga tgtactcgat	20
<210> 2 <211> 1 <212> D <213> A	.9	
<220> <223> V	/EGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> 2 gcttgaa	24 agat gtactcgat	19
<210> 2 <211> 1 <212> D <213> A	18	
<220> <223> V	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma	
<400> 2 cttgaag	25 gatg tactcgat	18

<210><211><212><213>	20		
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		·
<400> tggctt	26 tgaag atgtactcga		20
<210><211><212><212><213>	19		
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		
<400> tggctt	27 tgaag atgtactcg		19
<210><211><212><212><213>	33		
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		
<400> gggca	28 cacag gatggcttga agatgtactc gat		33.
<210><211><212><212><213>	23		
<220> <223>	VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma		·,
<400> gggca	29 cacag gatggcttga aga		23
<210><211><212><213>	62		
<220>	•	DEOT MAN	,

```
<221> CDS
<222> (2)...(61)
<223> VEGF-A
<400> 30
a gat cga gta cat ctt caa gcc atc ctg tgt gcc cct gat gcg atg cgg
                                                                         49
  Asp Arg Val His Leu Gln Ala Ile Leu Cys Ala Pro Asp Ala Met Arg
                                         10
                                                                         62
ggg ctg ctg caa t
Gly Leu Leu Gln
             20
<210> 31
<211> 62
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (1)...(60)
<223> VEGF-C
<400> 31
                                                                          48
cga caa aca cct tct tta aac ctc cat gtg tgt ccg tct aca gat gtg
Arg Gln Thr Pro Ser Leu Asn Leu His Val Cys Pro Ser Thr Asp Val
                                       10
                                                                          62
qqq qtt qct qca at
Gly Val Ala Ala
<210> 32
<211> 62
<212> DNA
<213> Homo sapiens
<220>
<221> CDS
<222> (2) . . . (61)
<223> VEGF-D
<400> 32
                                                                          49
g tac caa cac att ctt caa gcc ccc ttg tgt gaa cgt gtt ccg atg tgg
  Tyr Gln His Ile Leu Gln Ala Pro Leu Cys Glu Arg Val Pro Met Trp
                    5
                                         10
                                                                          62
tgg ctg ttg caa t
Trp Leu Leu Gln
              20
```

<210> 33

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Scrambled VEGF antisense oligonucleotide in Kaposi's sarcoma, ovarian carcinoma, and melanoma

<400> 33 tacgtagtat ggtgtacgat c

21